Strategies and testing methods for identifying mutagenic risks

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 455, Issue 1-2, 2000, Pages 3-20

  MacGregor, James T ^a   Casciano, Daniel ^b   Müller, Lutz ^c,d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^c Federal Institute for Drugs and Medical Devices   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Carcinogenicity; Harmonization; Mutagenicity; Testing guidelines

Indexed keywords

CHEMICAL MUTAGEN; DNA; DRUG; ENVIRONMENTAL MUTAGEN; MUTAGENIC AGENT;

ANALYTIC METHOD; CARCINOGENICITY; CHROMOSOME ABERRATION; DOSE RESPONSE; GENE EXPRESSION; GENE MUTATION; GENETIC TOXICOLOGY; HUMAN; MUTAGEN TESTING; MUTAGENICITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 0034693727     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(00)00116-0     Document Type: Article

References (162)

1. Chemical production of mutations
2. Origins of genetic toxicology and the Environmental Mutagen Society
3. Toxic substances control act (1976)
4. The detection of environmental mutagens
5. Detection of carcinogens as mutagens in the Salmonella/microsome test: Assay of 300 chemicals
6. Environmental mutagenesis: Past and future directions
7. Genetic toxicology
8. The GEN-TOX program: Genetic activity evaluation
9. Mutagenicity test schemes and guidelines: U.S. EPA, office of pollution prevention and toxics and office of pesticide programs
10. Toxicology testing requirements and the U.S.-Japan collaborative study on in vitro tests for chromosomal aberrations
11. Genotoxicity testing: Current practices and strategies used by the pharmaceutical industry
12. Genetic toxicology testing requirements: Official and unofficial views from Europe
13. The Japanese mutagenicity studies guidelines for pesticide registration
14. ICH-harmarmonised guidances on genotoxicity testing of pharmaceuticals: Evolution, reasoning and impact
15. Experience with mutagenicity testing of new drugs: Viewpoint of a regulatory agency
16. The quality of genotoxicity testing of drugs. Experiences of a regulatory agency with new and old compounds
17. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: Experience with pharmaceuticals
18. Genotoxicity tests for new chemicals in Germany: Routine in vitro systems
19. History and design of the study
20. Methods and testing strategies for evaluating the genotoxic potential of chemicals
21. ICPEMC Perspectives on the scientific basis of risk assessment in genetic toxicology
22. Recommendations for screening for potential human germ cell mutagens: An ICPEMC working paper
23. ICPEMC Testing for mutagens and carcinogens: The role of short-term genotoxicity assays. A report prepared by The International Commission for Pretection Against Environmental Carcinogens and Mutagens (ICPEMC)
24. Weight-of-evidence scheme for evaluation and interpretation of short-term results
25. A method for combining and comparing short-term genotoxicity test data
26. Achievements by CSGMT/JEMS/MMS (BMMS: The collaborative study group for the micronucleus test in the mammalian mutagenesis study group of the Environmental Mutagen Society of Japan
27. Evaluation of the rodent micronucleus assay in the screening of IARC carcinogens (Groups 1, 2A and 2B), the summary report of the 6th collaborative study by CSGMT/JEMS/MMS
28. Target organ and time-course in the mutagenicity of five carcinogens in MutaMouse(TM): A summary report of the second collaborative study of the transgenic mouse mutation assay by JEMS/MMS
29. Summary of major conclusions from the International Workshop on Genotoxicity Test Procedures (IWGTP)
30. Kinetics of induction of DNA adducts, cell proliferation and gene mutations in the liver of Muta(TM)Mice treated with 5,9-dimethyldibenzo(c,g)carbazole
31. Effect of mitogenic or regenerative cell proliferation on lacZ mutant frequency in the liver of Muta(TM)Mice treated with 5,9-dimethyldibenzo(c,g)carbazole
32. Diethylnitrosamine exposure-responses for DNA ethylation, hepatocellular proliferation, and intitiation of carcinogenesis in rat liver display non-linearities and thresholds
33. Kinetics of DNA adduct formation and removal in mouse hepatocytes following in vivo exposure to 5,9-dimethyldibenzo(c,g) carbazole
34. Dose-response and threshold-mediated mechanisms in mutagenesis
35. The genotoxicity and carcinogenicity of paracetamol: A regulatory (re)view
36. Sense and nonsense in toxicity assessment of medicinal products
37. Carcinogens are mutagens: A simple test system for combining liver homogenates for activation and bacteria for detection
38. Evaluation of four in vitro genetic toxicity tests for predicting rodent carcinogenicity: Confirmation of earlier results with 41 additional chemicals
39. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the U.S. NTP
40. IPCS harmonization of methods for the prediction and quantification of human carcinogenic/mutagenic hazard, and for indicating the probable mechanism of action of carcinogens
41. The prospects for a simplified and internationally harmonized approach to the detection of possible human carcinogens and mutagens
42. Genotoxicity under extreme culture conditions, a report from ICPEMC Task Group 9
43. Interpretation of the biological relevance of genotoxicity test results: The importance of thresholds
44. Cytotoxicity and chromosome aberrations in vitro: Experience in industry and the case for an upper limit on toxicity in the aberration assay
45. Appropriate levels of cytotoxicity for genotoxicity tests using mammalian cells in vitro
46. Too many rodent carcinogens: Mitogenesis increases mutagenesis
47. Challenge to the simple paradigm that carcinogens are mutagens and to the in vitro and in vivo assays used to test the paradigm
48. Chemical structure, Salmonella mutagenicity and extent of carcinogenicity as indicators of genotoxic carcinogenesis among 222 chemicals tested in rodents by the U.S. NCI/NTP
49. The influence of chemical structure on the extent and sites of carcinogenesis of 522 rodent carcinogens and 55 different human carcinogen exposures
50. Carcinogenicity results for 114 laboratory animal studies used to assess the predictivity of four in vitro genetic toxicity assays for rodent carcinogenicity
51. Transgenic animal models for mutagenesis studies: Role in mutagenesis research and regulatory testing
52. Finally, the book of life and instructions for navigating it
53. Chemical carcinogensis: Too many rodent carcinogens
54. Evaluation of the micronucleus test using a Chinese hamster cell line as an alternative to the conventional in vitro chromosomal aberration test
55. Comparative evaluation of the in vitro micronucleus test and the in vitro chromosome aberration test: Industrial experience
56. The CB in vitro micronucleus assay in human lymphocytes
57. Chemically induced aneuploidy
58. Report from the in vitro micronucleus assay working group
59. The single cell gel/Comet assay: Guidelines for in vitro and in vivo genetic toxicology testing
60. Monitoring environmental genotoxicants
61. Somatic gene mutations in humans
62. Mamalian cell genetics: II. Chemical induction of specific locus mutations in Chinese hamster cells in vitro
63. Detection and quantification of X-ray induced mutation in cultured diploid human fibroblasts
64. A quantitative assay of mutation induction at the hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells (CHO/HGPRT system): Development and definition of the system
65. Cytotoxicity and mutagenicity of alkylating agents in cultured mammalian cells (CHO/HGPRT system):mutagen treatment in the presence or absence of serum
66. Phenotypic lag and mutation to 6-thioguanine resistance in diploid human lymphoblasts
67. The use of Chinese hamster ovary cells for quantitative, specific locus mutation induction determination, and its applicability for mutagenicity testing of chemical substances: Report of a U.S. environmental protection agency genetic toxicology work group
68. Mammalian in vivo cytogenetic assays: Analysis of chromosome aberrations in bone marrow cells
69. Lifetime persistence and clonality of chromosome aberrations in the peripheral blood of mice acutely exposed to ionizing radiation
70. Numerical and structural abnormalities detected in human sperm with a combination of multicolor FISH assays
71. Fluorescence in situ hybridization to Y chromosomes in decondensed human sperm nuclei
72. Detection of hyperdiploidy and chromosome breakage in interphase human lymphocytes following exposure to the benzene metabolite hydroquinone using multicolor fluorescence in situ hybridization with DNA probes
73. Enumeration of 6-thioguanine-resistant peripheral blood lymphocytes in man as a potential test for somatic cell mutations arising in vivo
74. In vivo somatic mutations in humans: Measurement and analysis
75. T-cell cloning to detect the mutant 6-thioguanine resistant lymphocytes present in human peripheral blood
76. Somatic gene mutations in vivo as indicated by 6-thioguanine-resistant T-lymphocytes in human blood
77. Enumeration of thioguanine-resistant lymphocytes using autoradiography
78. Detection of somatic mutants in man: Hprt mutations in lymphocytes and hemoglobin mutations in erythrocytes
79. Autoradiographic detection of 6-thioguanine-resistant lymphocytes in mice: A novel system in somatic mutagenesis
80. A method to quantify spontaneous and in vivo induced thioguanine-resistant mouse lymphocytes
81. Factors that affect the frequency of thioguanine-resistant lynphocytes in mice following exposure to ethylnitrosourea
82. Measurement of in vivo mutant frequency in lymphocytes in the mouse
83. Further assessment of factors influencing measurements of thioguanine-resistant mutant frequency in circulating T-lymphocytes
84. HPRT mutant frequencies in circulating lymphocytes: Population studies using normal donors, exposed groups and cancer-prone syndrones
85. Factors influencing mutation at the hprt locus in T-lymphocytes: Studies in normal women and women with benign and malignant breast masses
86. Impact of age and environment on somatic mutation at the hprt gene of T-lymphocytes in humans
87. In vivo ionizing irradiations produce deletions in the hprt gene of human T-lymphocytes
88. The mutagenic effects of low level sub-acute inhalation exposure to benzene in CD-1 mice
89. 60Co gamma rays
90. Molecular analysis of hypoxanthine phosphoribosyl transferase mutants induced by glycidyl 1-napthyl ether in mouse spleen cells in vivo
91. A mouse model for the study of in vivo mutational spectra:sequence specificity of ethylene oxide at the hprt locus
92. Mutagenicity of butadiene and its epoxide metabolites: II. Mutational spectra of butadiene, 1, epoxybutane and diepoxybutane at the hprt locus in splenic T-cells from exposed B6C3F1 mice
93. Development of a cloning assay with high cloning efficiency to detect induction of 6-thioguanine-resistant lymphocytes in spleen of adult mice following in vivo inhalation exposure to 1,3-butadiene
94. Mutant frequency at the H-2K class 1 and hprt genes in T-lymphocytes from the X-ray exposed mouse
95. Induction of 6-thioguanine-resistant lymphocytes in Fischer 344 rats following in vivo exposure to N-ethyl-N-nitrosourea and cyclophosphamide
96. The effect of time after treatment, treatment schedule and animal age on the frequency of 6-thioguanine-resistant T-lymphocytes induced in Fischer 344 rats by N-ethyl-N-nitrosourea
97. Development and utilization of the rat lymphocyte hprt mutation assay
98. 6-alkylguanine in hprt mutagenesis in T-lymphocytes of rats exposed to ethylmethanessulfonate, N-(2-hydroxyethyl)-N-nitrosourea, or N-ethyl-N-nitrosourea
99. DNA adduct formation and T-lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene
100. Vitamin C intake influences cell proliferation and muatgenicity induced by benzo[a]pyrene (BP) and bleomycin (BM) in the rat
101. Lymphocyte mutant frequency in relation to DNA adduct formation in rats treated with tumorigenic doses of the mammary gland carcinogen 7,12-dimethylbenz[a]anthracene
102. Calorie restriction modulates chemically-induced in vivo somatic mutation frequency
103. Hprt and lacI mutant frequency in relation to DNA adduct formation in N-hydroxy-2-acetylaminofluorene-treated Big Blue® rats
104. 6-methyguanine in bone marrow and not in the spleen
105. Assessment of DNA adducts and the frequency of 6-thioguanine resistant T-lymphocytes in F344 rats fed 2,4-toluenediamine or implanted with toluendiisocyanate-containing polyester polyurethane foam
106. Efficient rescue of integrated shuttle vectors from transgenic mice: A model for studying mutations in vivo
107. LacZ transgenic mouse models: Their application in genetic toxicology
108. Transgenic animal models for detection of in vivo mutations
109. In vivo transgenic mutation assays
110. Comparison of somatic mutation in transgenic versus host locus
111. Comparison of in vivo mutagenesis in the endogenous Hprt gene and the lacI transgene of Big Blue® rats treated with 7,12-dimethylbenz[a]anthracene
112. Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice
113. A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections
114. ENU-induced mutagenesis at a single A:T base pair in transgenic mice containing φX174
115. Comparison of mutant frequencies and types of mutations induced by thiotepa in the endogenous Hprt gene and transgenic lacI gene of Big Blue® rats
116. Induction of lacZ mutation by 7,12-dimethylbenz[a]anthracene in various tissues of transgenic mice
117. Procarbazine genotoxicity in the Muta(TM)Mouse; strong clastogenicity and organ-specific induction of lacZ mutations
118. 4-Chloro-o-phenylenediamine induces a dose-related increase in GC>T:A transversions and one major DNA adduct in the liver of Big Blue® mice after 26 weeks of feed treatment
119. 2-Amino-3,8-dimethylimidazo[4,5-f]quinooxaline in lacI transgenic (Big Blue®) mice
120. Mutagenic activity of 4-nitroquinoline-N-oxide in upper aerodigestive tissue in lacZ [Muta(TM)Mouse] and the effects of 1,4-phenylenebis(methylene)selenocyanate
121. Increase in mutation frequency in lung of the Big Blue® rat by exposure to diesel exhaust
122. LacI mutation spectra following benzo[a]pyrene treatment of Big Blue® mice
123. Mutational analysis of the liver, colon, and kidney of Big Blue® rats treated with 2,amino-3-methylimadazo[4,5-fquinoloine]
124. Molecular analysis of mutations in the lacI and Hprt genes of N-hydroxy-2-acetylaminofluorene-treated Big Blue® rats
125. Relative sensitivity of the endogenous hprt gene and lacI transgene in ENU-treated B6CH3Fl mice
126. Mutagenic response of the endogenous hprt gene and lacI transgene in benzo[a]pyrene-treated Big Blue® B6C3HF1 mice
127. Frequency and spectrum of ethylnitrosourea-induced mutation at the hprt and lacI loci in splenic lymphocytes of exposed lacI transgenic mice
128. Comparison of in vivo mutagenesis in the transgene lacI with the endogenous gene hprt in Big Blue® rats exposed to DMBA
129. Comparison of the types of mutations induced by 7,12-dimethylbenz[a]anthracene in the lacI and hprt genes of Big Blue rats
130. Cyclophosphamide-induced mutations are detected at the hprt but not lacI loci on splenic T-cells of exposed Big Blue® mice
131. Assessment of the in vivo mutagenicity of ethylene oxide in the tissues of B6C3HF1 lacI transgenic mice following inhalation exposure
132. In vivo mutageicity of ethylene oxide at the hprt locus in T-lymphocytes of B6C3HF1 lacI transgenic mice following inhalation exposure
133. Evaluation of a plasmid-based transgenic mouse model for detecting in vivo mutations
134. APRT: A versatile in vivo resident reporter of local mutation and loss of heterozygosity
135. Development of a novel mouse tk(±) embryonic stem cell line for use in mutagenicity studies
136. Tk(±) mouse model for detecting in vivo mutation in an endogenous autosomal gene
137. Carcinogen-induced loss of heterozygosity at the Aprt locus of somatic cells of the mouse
138. A mutational assay system using the thymidine kinase locus in mouse lymphoma cells
139. High-frequency nonrandom mutational event at the adenine phosphoribosyltransferase (aprt) locus of sib-selected CHO variants heterozygous for aprt
140. Isolation of an APRT heterozygote from TK6 human lymphoblasts: Predominance of multilocus loss of heterozygosity among spontaneous APRT mutants
141. Geotypic selection methods for the direct analysis of point mutations
142. -7 by combining two genotypic selection methods, MutEx enrichment and allele-specific competitive blocker PCR
143. Global response of Saccharomyces cerevisiae to an alkylating agent